Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US7473761 | RECORDATI RARE | Somatostatin analogues |
Dec, 2026
(3 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8822637 | RECORDATI RARE | Somatostatin analogues |
Aug, 2023
(a month ago) | |
US7759308 | RECORDATI RARE | Microparticles comprising somatostatin analogues |
Oct, 2026
(3 years from now) | |
US9351923 | RECORDATI RARE | Extended-release composition comprising a somatostatin derivative in microparticles |
May, 2028
(4 years from now) |
Signifor Lar Kit is owned by Recordati Rare.
Signifor Lar Kit contains Pasireotide Pamoate.
Signifor Lar Kit has a total of 4 drug patents out of which 1 drug patent has expired.
Expired drug patents of Signifor Lar Kit are:
Signifor Lar Kit was authorised for market use on 15 December, 2014.
Signifor Lar Kit is available in for suspension;intramuscular dosage forms.
Signifor Lar Kit can be used as method of treating acromegaly.
The generics of Signifor Lar Kit are possible to be released after 23 May, 2028.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 29, 2025 |
Drugs and Companies using PASIREOTIDE PAMOATE ingredient
Market Authorisation Date: 15 December, 2014
Treatment: Method of treating acromegaly
Dosage: FOR SUSPENSION;INTRAMUSCULAR
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic